Twist Bioscience Co. (NASDAQ:TWST) Stake Lowered by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company cut its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 3.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,001 shares of the company’s stock after selling 1,063 shares during the period. The Manufacturers Life Insurance Company’s holdings in Twist Bioscience were worth $1,355,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of TWST. Signaturefd LLC boosted its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new stake in Twist Bioscience in the second quarter worth $43,000. Blue Trust Inc. boosted its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Twist Bioscience in the second quarter worth $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 856 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total value of $35,789.36. Following the transaction, the chief financial officer now owns 73,397 shares in the company, valued at approximately $3,068,728.57. This represents a 1.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 1,730 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the transaction, the chief executive officer now owns 495,523 shares in the company, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 101,787 shares of company stock worth $4,584,508. Insiders own 3.92% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on TWST shares. TD Cowen restated a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Barclays decreased their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Scotiabank upped their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. Finally, Evercore ISI upped their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and an average price target of $51.00.

Twist Bioscience Stock Down 0.2 %

Shares of NASDAQ:TWST opened at $51.56 on Wednesday. Twist Bioscience Co. has a 12 month low of $26.51 and a 12 month high of $60.90. The company’s fifty day simple moving average is $44.65 and its 200 day simple moving average is $46.58. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of -14.32 and a beta of 1.82.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.